Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Cutaneous Lymphomas

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Modern Hypofractionation Schedules for Tangential Whole Breast Irradiation Decrease the Fraction Size-corrected Dose to the Heart

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Radiotherapy studies and extra-nodal non-Hodgkin lymphomas, progress and challenges

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Frequency of Opioid Use in a Population of Cancer Patients During the Trajectory of the Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Systemic Treatment of Psoriasis with JAK Inhibitors: A Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

Primary cutaneous lymphomas are the second most common form of extra-nodal lymphomas. They have special characteristics compared with other lymphomas. They are most frequently of T-cell origin and they generally have a much more indolent course than lymphomas of similar histology in other locations. Mycosis fungoides is the most common type of cutaneous lymphoma. Primary cutaneous lymphomas remain confined to the skin for a long time. Skin-directed therapies are the main treatments; systemic treatments are not very effective for the skin lesions. Skin-directed therapies used for the early and thin lesions are topical corticosteroids, phototherapy and topical retinoids and, for the more widespread or thick lesions, topical nitrogen mustard and radiation. Radiation therapy is highly effective and is indicated in virtually all cases of localised disease. Radiation therapy may be given to the whole skin surface, so-called total skin electron beam therapy. However, if the disease spreads to other organs, systemic treatments are indicated, often combined with skin-directed therapies. Conventional cytotoxic therapy is less effective in cutaneous lymphomas. The commonly used therapies, such as interferon, enhanced anti-tumour immunity and the recent advances in immune therapies may improve our treatments for cutaneous lymphomas.

TidsskriftClinical oncology (Royal College of Radiologists (Great Britain))
Udgave nummer11
Sider (fra-til)797-807
Antal sider11
StatusUdgivet - nov. 2019

Bibliografisk note

Copyright © 2019 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

ID: 59075551